US Edition
FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
7 Articles
7 Articles
Medical Dialogues
hcplive.comFDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
The FDA has approved preodnisolone acetate ophthalmic suspension, USP 1%, for treating steroid-responsive ocular inflammation. Amneal Pharmaceuticals plans to launch the product in Q3...
Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals announced the FDA approval of prednisolone acetate ophthalmic suspension 1% sterile, which references Pred Forte (Allergan, an AbbVie company). Launch of the product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation. The most commonly reported advers…
The spin-off Avizorex Pharma, S.L. (AVX Pharma) of the Miguel Hernández de Elche University Science Park (PCUMH) was born with the aim of developing treatments for dry eye syndrome. To accelerate the development of its first product, the company signed its sale in 2019 to the company Aerie Pharmaceuticals (Aerie), later acquired by the multinational Alcon. Recently, the latter has announced that the Food and Drug Administration of the United Sta…
Amneal gets FDA approval for prednisolone acetate ophthalmic suspension
BRIDGEWATER, N.J. – Amneal Pharmaceuticals, Inc. (Amneal) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory a…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
